Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
patients who will undergo elective open nephrectomy will be divided into three groups; the control (PCA), the erector spina plane block, and the quadratus lumborum block. After standard anesthesia induction and monitorization then Bispectral index monitoring will be applied to all patients. Anesthesia will be maintained using sevoflurane in a mixture of oxygen and air. Continuous remifentanil infusion will be used for analgesia. Then patient's numeric rating scales and morphine pca consumptions will be recorded for one day.
patients who will undergo elective open nephrectomy will be divided into three groups; the control (PCA), the erector spina plane block and the quadratus lumborum block. After standard anesthesia induction and monitorization then Bispectral index monitoring will be applied to all patients. Anesthesia will be maintained using sevoflurane in a mixture of oxygen and air. Continious remifentanil infusion will be used for analgesia. Then patient's numeric rating scales and morphine pca consumptions will be recorded for one day.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patient controlled analgesia | Placebo Comparator | this group of patients received no block, received only postoperative patient-controlled analgesia with morphine |
|
| erector spina plane block | Active Comparator | this group of patients received erector spina plane block preoperatively, received only postoperative patient-controlled analgesia with morphine |
|
| quadratus lumborum block | Active Comparator | this group of patients received erector spina plane block preoperatively, received only postoperative patient-controlled analgesia with morphine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| preoperative remifentanil consumption | Procedure | continuous remifentanil infusion will applied for peroperative analgesia |
|
| Measure | Description | Time Frame |
|---|---|---|
| postoperative morphine consumption | amount of postoperative morphine use of the patient's | 24 hour postoperatively |
| Measure | Description | Time Frame |
|---|---|---|
| peroperative remifentanil consumptions | amount of remifentanil use of the patient's | 4 hour preoperatively |
| numeric rating scale | numeric rating scores of the patient's postoepartively |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| zehra ipek Arslan AYDIN, Professor | Contact | 00905325011339 | zehraipek48@gmail.com | |
| Zehra ipek Arslan, Professor | Contact | 00905325011339 | zehraipek48@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kocaeli University Medical Faculty | Recruiting | İzmit | 41100 | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
participant will not know which block applied, and the outcome assessor of the postoperative analgesia will not know
| postopeartive controlled anlagesia with morphine | Procedure | postoperative morphine patient controlled analgesia will be applied for postoperative analgesia |
|
| 24 hour postoperatively |
| Kocaeli University Medical Faculty | Active, not recruiting | Kocaeli | Turkey (Türkiye) |
| ID | Term |
|---|---|
| D002292 | Carcinoma, Renal Cell |
| D000377 | Agnosia |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D007680 | Kidney Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D010468 | Perceptual Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D009020 | Morphine |
| ID | Term |
|---|---|
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
Not provided
Not provided